A systematic review proposed that patients may benefit from rigorous retesting of several agents (e.g., drugs such as -lipoic acid, duloxetine, glutathione, and vitamin E) to extend and validate the evidence of American Society of Clinical Oncology (ASCO) recommendations for CIPN management [82]
Because crystalline CoQ10 has low water solubility and poor powder dispersibility, its commercial performance depends strongly on carrier oil selection, particle-size control, and dosage-form engineering
bromii , fecal hydroquinone, L-cystine, and 12-keto-tetrahydro-LTB4 in the differentiation of mild, moderate, and advanced CKD patients from healthy controls
Limited research exists on the use of P